| |
Finally, a single source to solve all your HCP information requirements! IQVIA's Infinite Dimension Profiler enables advanced personalization and deeper HCP engagement, ultimately improving patient outcomes. Download the fact sheet now. 
|
|
| By Eric Sagonowsky,Kevin Dunleavy,Angus Liu,Fraiser Kansteiner,Zoey Becker Last year, the value of the top 10 M&A deals in the biopharma industry came to $115.8 billion, outranking prior sums from 2022, 2021 and 2020, which came to $65 billion, $53 billion and $97 billion, respectively. This report breaks down the industry's 10 largest M&A agreements of the year. |
|
|
|
By Nick Paul Taylor Sanofi is stepping up support for employees with cancer and other critical illnesses, agreeing to secure their jobs, salaries and benefits for at least 12 months after diagnosis regardless of their location or role. |
By Andrea Park After losing a patent infringement lawsuit last year that ended with an order to pay out $31 million in damages, leaving it all but hanging by a thread, NanoString is plotting a new way forward. |
By Nick Paul Taylor Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday, when the drugmaker axed a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline. |
By Fraiser Kansteiner Locked in a heated battle with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity. |
By Fraiser Kansteiner Late last month, Novo Holdings’ CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash. Now, a major deal has materialized. |
By Fraiser Kansteiner Rumblings of a potential bidding war over cancer specialist MorphoSys have subsided as quickly as they arose after Novartis descended on the German biotech Monday with billions of dollars in cash. The move comes less than 24 hours after rumors of the M&A imbroglio surfaced in Reuters. |
By Helen Floersh,Gabrielle Masson Amgen's obesity drug MariTide stimulates weight loss in animals and people without major side effects, new data from the company show. And unlike its competitors, it may only need to be taken once a month and perhaps not for life. |
By Angus Liu After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023. |
By Andrea Park That brings the total number of medical device reports received since April 2021 to more than 116,000, with 561 reported deaths. |
By Annalee Armstrong,Zoey Becker With supply strains not letting up in the growing injectable obesity med market, Lilly looks to carve out manufacturing early for its oral candidate. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper Supercharge Your Field Deployment in 2024 with Engaging, Clinically-Oriented and Influential FRMs, MSLs, NAMs and CNEs. Krista Pinto, President, Field Deployment, EVERSANA |
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
